静脉给前列腺素E_1治疗PAOD的临床研究

Management of Peripheral Arterial Occlusive Disease with PGE1·CD Intravenously

目的:临床评价静脉给保达新(PGE1·CD)治疗PAOD的有效性及安全性。方法:6例经静脉滴注保达新28d。分析治疗前后溃疡缩小率、溃疡面积、踝肱指数、经皮氧分压等客观指标及静息痛、冷感等主观指标改变,确定疗效;分析与治疗有关的不良反应发生情况,作安全性评估。结果:溃疡面积与治疗前相比明显缩小,有显著差异(P<0.05);溃疡缩小率为64.6％;静息痛、冷感等主观指标的改善率达到100％;经皮氧分压比治疗前明显提高(P<0.05)。与药物有关的不良反应率为100％。结论:PGE1治疗PAOD病是安全有效的。

Objective: To study the efficiency and safety of PGE1 - CD intravenous infusion in the treatment of PAOD. Methods: Six cases were enrolled in the study. The PGE1 - CD was used through intravenous infusion for 28 days. We observed the ulcer reducing rate, ulcer area, ABI (ankle/brachial index), TcPo2 and rest pain as well as the coldness before and after the PGE1 - CD application to analyze the effect of PGE1 - CD. Assess the safety of PGE1 - CD through the comparison of the vital signs, lab examination and side -effect before and after the PGEl-CD application. Results: Compared with that before the test, the ulcer area decreased significantly (P<0.05) and the ulcer reducing rate was 64.6%. Furthermore, the improvement rate of rest pain and coldness in the study group was 100% . After the drug application, the TcPo2 showed significant improvement (P < 0.05 ). The ABI level also had no increment from the base level. The incidence rate of the drug - related side effect got to 100%. Conclusion: Intravenous PGE1 is safety and effective to treat PAOD.